Literature DB >> 31393022

Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Ahmet Emre Eşkazan1.   

Abstract

Entities:  

Keywords:  adverse event; chronic myeloid leukaemia; haematologic toxicity; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2019        PMID： 31393022      PMCID： PMC6783590          DOI： 10.1111/bcp.14092

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  14 in total

1.  Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Authors:  Ahmet Emre Eskazan; Deniz Ozmen
Journal:  Expert Rev Hematol       Date:  2017-06-13       Impact factor: 2.929

2.  Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

3.  Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Authors:  Masahiro Kizaki; Naoto Takahashi; Noriyoshi Iriyama; Shinichiro Okamoto; Takaaki Ono; Noriko Usui; Koiti Inokuchi; Chiaki Nakaseko; Mineo Kurokawa; Masahiko Sumi; Fumihiko Nakamura; Tatsuya Kawaguchi; Ritsuro Suzuki; Kazuhito Yamamoto; Kazunori Ohnishi; Itaru Matsumura; Tomoki Naoe
Journal:  Int J Hematol       Date:  2019-02-14       Impact factor: 2.490

Review 4.  The rationale of dose-response curves in selecting cancer drug dosing.

Authors:  Jennifer H Martin; Simon Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-06-20       Impact factor: 4.335

Review 5.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

6.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Authors:  Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

7.  Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Kiran Naqvi; Elias Jabbour; Jeffrey Skinner; Musa Yilmaz; Alessandra Ferrajoli; Prithviraj Bose; Philip Thompson; Yesid Alvarado; Nitin Jain; Koichi Takahashi; Jan Burger; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Shilpa Paul; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

Review 8.  Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Authors:  Ahmet Emre Eskazan; Dilek Keskin
Journal:  Ther Adv Hematol       Date:  2017-07-25

9.  Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Shuichi Ota; Toshihiro Matsukawa; Satoshi Yamamoto; Shinichi Ito; Motohiro Shindo; Kazuya Sato; Takeshi Kondo; Kyuhei Kohda; Hajime Sakai; Akio Mori; Tohru Takahashi; Hiroshi Ikeda; Hiroyuki Kuroda; Yoshihito Haseyama; Masaki Yamamoto; Takeo Sarashina; Makoto Yoshida; Ryoji Kobayashi; Mitsufumi Nishio; Toshimichi Ishihara; Yasuo Hirayama; Yasutaka Kakinoki; Hajime Kobayashi; Takashi Fukuhara; Masahiro Imamura; Mitsutoshi Kurosawa
Journal:  Eur J Haematol       Date:  2018-05-23       Impact factor: 2.997

10.  A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.

Authors:  Koichi Takahashi; Hagop M Kantarjian; Yulong Yang; Koji Sasaki; Preetesh Jain; Sara DellaSala; Farhad Ravandi; Tapan Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Guillermo Garcia-Manero; Elias Jabbour; Jorge E Cortes
Journal:  Cancer       Date:  2016-08-10       Impact factor: 6.860
View more
  2 in total

1.  Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2020-05-20       Impact factor: 4.335

2.  COVID-19-Induced Pancytopenia in a Major Molecular Response CML Patient on Dasatinib: A Case Report and Review of the Literature.

Authors:  Balraj Singh; Sarah Ayad; Parminder Kaur; Vinod Kumar; Sachin Gupta; Michael Maroules
Journal:  Eur J Case Rep Intern Med       Date:  2021-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.